Xingqi Pharmaceutical announced that the company received the “Drug Supplement Application Approval Notice” for atropine sulfate eye drops approved and issued by the State Drug Administration. The drug specifications are 0.02% and 0.04%, and the indication is to slow the progression of myopia in children aged 6 to 12. The drug approval number is valid until 2029 March 4.

Xingqi Pharmaceutical announced that the company received the “Drug Supplement Application Approval Notice” for atropine sulfate eye drops approved and issued by the State Drug Administration. The drug specifications are 0.02% and 0.04%, and the indication is to slow the progression of myopia in children aged 6 to 12. The drug approval number is valid until 2029 March 4.